Clinical benefit must not be confused with cost benefit

BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7127.311 (Published 24 January 1998) Cite this as: BMJ 1998;316:311
  1. Michael D Rawlins, Chairmana,
  2. Alasdair M Breckenridge, Vice chairmana
  1. a Committee on Safety of Medicines, London SW8 5NQ

    Editor—In their letter about drug licensing Milner et al make two proposals: that the criteria for licensing new drugs in Britain should be changed and that the Medicines Control Agency (and, by implication, the Committee on Safety of Medicines) should adopt a (presumably more) rigorous standard of clinical effectiveness.1

    Readers should be aware that it is not possible for Britain, alone, to change …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription